These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15748144)

  • 1. The direct thrombin inhibitor melagatran/ximelagatran.
    Bereznicki LR; Jackson SL; Peterson GM
    Med J Aust; 2005 Mar; 182(5):254-5. PubMed ID: 15748144
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP
    Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ximelagatran for stroke prevention.
    Perret-Guillaume C; Wahl D
    JAMA; 2005 Jun; 293(23):2860-1; author reply 2861. PubMed ID: 15956626
    [No Abstract]   [Full Text] [Related]  

  • 5. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran: direct thrombin inhibitor.
    Ho SJ; Brighton TA
    Vasc Health Risk Manag; 2006; 2(1):49-58. PubMed ID: 17319469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
    Steurer J
    Praxis (Bern 1994); 2014 Jun; 103(13):785-6. PubMed ID: 24938162
    [No Abstract]   [Full Text] [Related]  

  • 11. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: both sides of the story.
    Testa L; Van Gaal W; Agostoni P; Abbate A; Trotta G; Biondi-Zoccai GG
    Stroke; 2007 Jul; 38(7):e57. PubMed ID: 17510448
    [No Abstract]   [Full Text] [Related]  

  • 13. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Cavuşoğlu Y
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
    [No Abstract]   [Full Text] [Related]  

  • 15. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
    Hankey GJ; Klijn CJ; Eikelboom JW
    Stroke; 2004 Feb; 35(2):389-91. PubMed ID: 14757889
    [No Abstract]   [Full Text] [Related]  

  • 18. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
    Bååthe S; Hamrén B; Karlsson MO; Wollbratt M; Grind M; Eriksson UG
    Clin Pharmacokinet; 2006; 45(8):803-19. PubMed ID: 16884319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.